TY - JOUR
T1 - Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
AU - Beal, Eliza W.
AU - Ahmed, Ahmed
AU - Grotz, Travis
AU - Leiting, Jennifer
AU - Fournier, Keith F.
AU - Lee, Andrew J.
AU - Dineen, Sean
AU - Dessureault, Sophie
AU - Baumgartner, Joel M.
AU - Veerapong, Jula
AU - Clarke, Callisia
AU - Strong, Erin
AU - Maithel, Shishir K.
AU - Zaidi, Mohammad Y.
AU - Patel, Sameer
AU - Dhar, Vikrom
AU - Hendrix, Ryan
AU - Lambert, Laura
AU - Johnston, Fabian
AU - Fackche, Nadege
AU - Raoof, Mustafa
AU - LaRocca, Christopher
AU - Ronnekleiv-Kelly, Sean
AU - Pokrzywa, Courtney
AU - Pawlik, Timothy M.
AU - Abdel-Misih, Sherif
AU - Cloyd, Jordan M.
PY - 2020/3
Y1 - 2020/3
N2 - Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). Methods: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013–2017 (P2). Results: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). Conclusion: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.
AB - Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). Methods: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013–2017 (P2). Results: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). Conclusion: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.
KW - Cytoreductive surgery
KW - Hyperthermic intraperitoneal chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85072399201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072399201&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2019.09.017
DO - 10.1016/j.amjsurg.2019.09.017
M3 - Article
C2 - 31558307
AN - SCOPUS:85072399201
SN - 0002-9610
VL - 219
SP - 478
EP - 483
JO - American journal of surgery
JF - American journal of surgery
IS - 3
ER -